Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Dare Bioscience (DARE) EBT Margin (2016 - 2025)

Dare Bioscience's EBT Margin history spans 6 years, with the latest figure at 143.72% for Q4 2025.

  • For Q4 2025, EBT Margin fell 860948.0% year-over-year to 143.72%; the TTM value through Dec 2025 reached 1313.32%, up 23961564.0%, while the annual FY2025 figure was 1315.51%, 23837669.0% up from the prior year.
  • EBT Margin reached 143.72% in Q4 2025 per DARE's latest filing, up from 162340.76% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 18079.54% in Q2 2025 to a low of 162340.76% in Q3 2025.
  • Average EBT Margin over 4 years is 24096.5%, with a median of 839.64% recorded in 2023.
  • The largest YoY upside for EBT Margin was 5087866bps in 2025 against a maximum downside of -15111208bps in 2025.
  • A 4-year view of EBT Margin shows it stood at 3.84% in 2022, then plummeted by -7543bps to 286.05% in 2023, then soared by 3060bps to 8465.75% in 2024, then plummeted by -102bps to 143.72% in 2025.
  • Per Business Quant, the three most recent readings for DARE's EBT Margin are 143.72% (Q4 2025), 162340.76% (Q3 2025), and 18079.54% (Q2 2025).